電子カルテ(EHR)：医療における将来のカルテ記入

1960年代以降、電子カルテ(EHR)の利用は限られたものとなっていましたが、米国政府が重視するようになってから導入は大きく促進されています。2004年にはブッシュ大統領が10年以内に全国民へEHRを適用するという目標を提示し、2009年にはオバマ大統領がARRA(米国復興・再投資法)の下で財源の主要素を追加しました。

当レポートでは、米国における電子カルテ(EHR)の利用動向について調査し、EHR利用の背後にある批判の理解と評価、EHR導入が直面する課題の分析、米国におけるEHRの発展に政府が果たしている役割と現在の利用に関する議論、世界におけるEHRシステム開発の試みおよび、製薬産業にとってのEHR利用の潜在的メリットなどをまとめ、概略以下の構成でお届けします。

エグゼクティブサマリー

第1章　電子カルテ(EHR)の発展

• 定義
• 初期の利用
• 改革前のプログラム
• EHRのための医療制度改革プログラム
• インセンティブプログラムの有意義な利用
• EHRの選挙後の方向性

第2章　技術

• EHRシステム
• モバイル技術
• HIPAAおよびプライバシー

第3章　EHRの導入

• 導入率
• 医師の意見
• 医師−患者関係への影響
• 実行課題

第4章　EHR利用の影響

• ケーススタディ：糖尿病
• ケーススタディ：診断画像
• ケーススタディ：予防治療
• ケーススタディ：薬物安全性

第5章　米国以外のEHR利用

• カナダ
• 欧州
• アジア
• 新興市場
• 実行の教訓

第6章　EHRの展望

• 政治
• 課金
• クローン作成
• CBRの見解

付録

Electronic Health Records have been in limited use since the 1960s, but their adoption received a major boost when they became more of a focus for the US government. In 2004, President Bush put forth the goal of having every American covered by an EHR within 10 years. In 2009, President Obama added the key element of funding under the American Recovery and Reinvestment Act. The EHR Meaningful Use Incentive programs funded under the ARA were further bolstered by programs in the 2010 health care reform legislation which promoted Accountable Care Organizations.

After the results of the November elections and the Supreme Court's ruling upholding the individual mandate, the future for health care reform would look more sure. However, recently some Republican members of congress have turned their attention to EHR programs, questioning whether they are an effective use of funding.

The report, “Electronic Health Records - Charting the Future of Health Care”, was designed to provide insights and analysis on a topic that is being felt from government agencies to treating physicians, while also impacting the pharmaceutical industry. CBR Pharma Insights not only provides in-depth analysis on the technology being used, the adoption of this technology, and the trends being seen locally and globally, but also how EHRs could impact pharmaceutical companies.

Key Reasons to Purchase

• Understand and evaluate the criticisms behind the use of Electronic Health Records
• Analyze the challenges facing Electronic Health Records adoption
• Understand the role government has played in the development of Electronic Health Records in the US and the debates that are currently taking place over their use
• Gain insights around the attempts being made to develop Electronic Health Records systems throughout the world, where they are showing positive signs of success, and where more work needs to be done
• Assess the potential benefits of the use of Electronic Health Records for the pharmaceutical industry and the opportunities that exist for your company

Table of Contents

Executive Summary

Chapter 1: Development of Electronic Health Records

• Definition
• Early use
• Pre-reform programs
• 2010 Health Care reform programs for EHRs
• Meaningful Use incentive programs
• Post-election direction for EHRs

Chapter 2: Technology

• EHR systems
• Mobile technology
• HIPAA and privacy

Chapter 3: Adoption of EHRs

• Adoption rates
• Physician opinions
• Impact on the physician-patient relationship
• Implementation challenges

Chapter 4: Impact of EHR use

• Case study: Diabetes
• Case study: Diagnostic imaging
• Case study: preventative care
• Case study: drug safety

Chapter 5: EHR use outside of the US

• Canada
• Europe
• Asia
• Emerging markets
• Lessons of implementation

Chapter 6: The outlook for EHRs

• Politics
• Billing
• Cloning
• The CBR View

Appendix